A Phase III Placebo-Controlled Trial Of Celecoxib In Genotype Positive Subjects With Familial Adenomatous Polyposis
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
To compare the time from randomization to treatment failure over a 5 year period in subjects treated with celecoxib vs placebo.
5 years
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A3191193
NCT00585312
September 2006
January 2019
Name | Location |
---|---|
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Cincinnait, Ohio 45236 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Omaha, Nebraska 68198 |
Pfizer Investigational Site | Bristol, Tennessee 37620 |
Pfizer Investigational Site | Salt Lake City, Utah 84112 |